Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q09328
UPID:
MGT5A_HUMAN
Alternative names:
Alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase V; GlcNAc-T V; Mannoside acetylglucosaminyltransferase 5; N-acetylglucosaminyl-transferase V
Alternative UPACC:
Q09328; D3DP70
Background:
Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A, also known as MGAT5, plays a pivotal role in the biosynthesis of complex N-glycans. These glycans are crucial for the proper function of proteins like EGFR, TGFR, and CDH2, influencing cellular signaling, actin cytoskeleton reorganization, cell-cell adhesion, and migration. MGAT5's activity is essential for enhancing growth factor-mediated signaling pathways, including those activated by FGF2, PDGF, IGF, TGFB1, and EGF.
Therapeutic significance:
Understanding the role of Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A could open doors to potential therapeutic strategies.